MaxWell Biosciences is biotechnology for optimizing cognitive performance and health span.
Maxwell Biosciences is a preclinical stage drug platform company actively developing an entirely new CLAROMER™ biotechnology platform which creates low molecular weight compounds which mimic peptides and are functionally distinct from macromolecules due to the ease of penetrating membranes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 10, 2022 | Seed | $10.80M | 4 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Seed |
|
— | Seed |
|
— | Seed |
![]() |
— | Seed |